Study #2022-0585
Window-of-opportunity trial of Ulixertinib for MAPK-activated gliomas
MD Anderson Study Status
Enrolling
Treatment Agent
Ulixertinib
Description
To learn if the study drug, ulixertinib, can cross over the blood-brain barrier in patients with recurrent brain tumors
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Gliomas
Study phase:
Phase I (Early)
Physician name:
Nazanin Majd
Department:
Neuro-Oncology
For general questions about clinical trials:
1-844-335-2276
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.